Investors

2015 Press Releases

Webcast ImageWebcast
Regulatory Update for Voxelotor (Replay)
12/03/18 at 8:30 a.m. ET
Regulatory Update for Voxelotor
Monday, December 3, 2018 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting (Replay)
12/03/18 at 3:00 p.m. ET
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting
3:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Supporting Materials
Download Event Supporting Material ASH IR Event Presentation Slides
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/31/15Global Blood Therapeutics Receives FDA Orphan Drug Designation for GBT440 in Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., Dec. 31, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease (SCD). GBT440 is being developed as a potentially disease-modifying therapy ... 
Printer Friendly Version
12/06/15Global Blood Therapeutics Announces Positive Phase 1/2 Data Supporting Development of GBT440 as a Potentially Disease-Modifying Therapy for Sickle Cell Disease
Results to be Presented During an Oral Session at the American Society of Hematology (ASH) Annual Meeting and Exposition Tomorrow, December 7 at 10:45 a.m. ET Company to Host Webcast Tomorrow at 12:30 p.m. ET to Discuss Data SOUTH SAN FRANCISCO, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announc... 
Printer Friendly Version
11/30/15Global Blood Therapeutics Announces Upcoming Investor Webcasts Including Event to Highlight GBT440 Data in Sickle Cell Disease at ASH
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced two upcoming investor webcasts.  On Monday, December 7 at 12:30 p.m. Eastern Time (ET), members of GBT’s management team and distinguished expert, Dr. Claire Hemmaway, MA (Hons) Cantab, MBBS, FRCP, FRCPATH, Queens Hospit... 
Printer Friendly Version
11/12/15Global Blood Therapeutics Reports Recent Business Progress and Third Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today reported business progress and financial results for the quarter ended September 30, 2015. “With the proceeds from our IPO, we are well positioned to increase the momentum across our proprietary product portfolio aimed at revolutioniz... 
Printer Friendly Version
11/10/15Global Blood Therapeutics Announces Multiple Data Presentations Supporting GBT440 Program for Hypoxemic Pulmonary Disorders, Including Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that new preclinical data supporting the development of GBT440 for the treatment of hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF), were presented at the American Heart Association (AHA) Scientific... 
Printer Friendly Version
11/05/15Global Blood Therapeutics Announces New GBT440 Data in Sickle Cell Disease to be Presented at the American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that data from the ongoing Phase 1/2 GBT440-001 study of GBT440 will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. Data will include an oral presentation of cli... 
Printer Friendly Version
10/14/15Global Blood Therapeutics to Present at BIO Investor Forum
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that its chief executive officer, Ted W. Love, M.D., will present a corporate update at the 14th Annual BIO Investor Forum on Wednesday, October 21, at 2 p.m. Pacific Time at the Parc 55 San Francisco. The presentation will be web... 
Printer Friendly Version
10/12/15Global Blood Therapeutics Announces GBT440 Receives FDA Fast Track Designation for Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GBT440 for the treatment of sickle cell disease (SCD).  “By granting Fast Track designation to GBT440, the FDA is acknowledging that SCD is a s... 
Printer Friendly Version
09/24/15Global Blood Therapeutics Appoints Philip A. Pizzo, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the appointment of Philip A. Pizzo, M.D., founding director of the Stanford Distinguished Careers Institute and former Dean of Stanford University School of Medicine, to the Company's Board of Directors. "We are delighted to expan... 
Printer Friendly Version
09/03/15Global Blood Therapeutics Announces Participation at Three September Conferences
Corporate Presentations Planned for Rodman & Renshaw, BioCentury NewsMakers and Morgan Stanley Conferences SOUTH SAN FRANCISCO, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced that the company's chief executive officer, Ted W. Love, M.D., will deliver corporate presentations at three upcoming... 
Printer Friendly Version
08/17/15Global Blood Therapeutics Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/17/15 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the closing of its initial public offering of 6,900,000 shares of common stock at an initial public offering price of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 900,000... 
Printer Friendly Version
08/11/15Global Blood Therapeutics Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, CA--(Marketwired - Aug 11, 2015) - Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at an initial public offering price of $20.00 per share. All shares of common stock are being offered by GBT. In addition, the underwriters have a 30-day option to purch... 
Printer Friendly Version
04/14/15Global Blood Therapeutics Appoints New Chief Business and Strategy Officer
... 
Printer Friendly Version
04/02/15Global Blood Therapeutics Appoints Two New Board Members
... 
Printer Friendly Version
02/10/15Global Blood Therapeutics Strengthens Management Team with Addition of Vice President of Program Leadership and Business Strategy
... 
Printer Friendly Version
02/05/15Global Blood Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
... 
Printer Friendly Version
01/12/15Global Blood Therapeutics Announces First Cohort Dosed in Phase I/II Trial of GBT440 in Sickle Cell Disease
... 
Printer Friendly Version
01/08/15Willie L. Brown, Jr. Joins the Board of Directors of Global Blood Therapeutics
... 
Printer Friendly Version
01/06/15Global Blood Therapeutics Completes $48 Million Series B Financing
... 
Printer Friendly Version
01/05/15Global Blood Therapeutics to Present at Upcoming Investor Conferences
... 
Printer Friendly Version